PMID- 19647299
OWN - NLM
STAT- MEDLINE
DCOM- 20091123
LR  - 20220331
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Print)
IS  - 0090-4295 (Linking)
VI  - 74
IP  - 5
DP  - 2009 Nov
TI  - Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a 
      novel assay using branched DNA.
PG  - 1156-61
LID - 10.1016/j.urology.2009.01.087 [doi]
AB  - OBJECTIVES: To develop a novel assay that uses branched DNA technology to measure 
      TMPRSS2-ERG fusion, as genetic rearrangement of TMPRSS2 regulatory sequences and 
      coding sequences of the ERG gene has been detected in nearly half of prostate 
      cancers, but quantitative assays to detect such TMPRSS2-ERG gene fusion have been 
      limited to real-time polymerase chain reaction (PCR) techniques that rely on 
      reverse transcriptase-based amplification. METHODS: Branched DNA probes were 
      designed to detect TMPRSS2-ERG gene fusion in prostate cancer cell lines. 
      Nonquantitative nested reverse transcription (RT)-PCR and fluorescence in situ 
      hybridization (FISH) were used to ascertain TMPRSS2-ERG gene fusion status in 
      prostate tissues. RESULTS: The branched DNA assay detected TMPRSS2-ERG gene 
      fusion from less than 200 pg of prostate cancer RNA, whereas more than 600 pg of 
      RNA was required for fusion gene detection by one step real-time RT-PCR. In 
      evaluation of clinical prostatectomy specimens, the branched DNA assay showed a 
      concordant detectable fusion signal in all 9 clinical samples that had fusion 
      detected by nested RT-PCR or FISH. Moreover, branched DNA detected gene fusion in 
      2 of 16 prostate cancer tissue specimens that was not detected by FISH or nested 
      RT-PCR. CONCLUSIONS: Our findings demonstrate a branched DNA assay that is 
      effective for detection of TMPRSS2-ERG gene fusion in prostate cancer clinical 
      specimens, thus providing an alternative method to ascertain TMPRSS2-ERG gene 
      fusion in human prostate cancer tissue.
FAU - Lu, Bin
AU  - Lu B
AD  - Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, Massachusetts 02115, USA.
FAU - Maqsodi, Botoul
AU  - Maqsodi B
FAU - Yang, Wen
AU  - Yang W
FAU - McMaster, Gary K
AU  - McMaster GK
FAU - Perner, Sven
AU  - Perner S
FAU - Regan, Meredith
AU  - Regan M
FAU - Bubley, Glenn J
AU  - Bubley GJ
FAU - Balk, Steven P
AU  - Balk SP
FAU - Rubin, Mark
AU  - Rubin M
FAU - Sanda, Martin G
AU  - Sanda MG
LA  - eng
GR  - U01 CA113913/CA/NCI NIH HHS/United States
GR  - U01 CA113913-04/CA/NCI NIH HHS/United States
GR  - UO1-CA11391/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090803
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
SB  - IM
CIN - Urology. 2009 Nov;74(5):1161-2; author reply 1162. PMID: 19883848
MH  - *Branched DNA Signal Amplification Assay
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - *Oncogene Fusion
MH  - Oncogene Proteins, Fusion/*analysis/*biosynthesis
MH  - Prostatic Neoplasms/*genetics
PMC - PMC2784207
MID - NIHMS136151
EDAT- 2009/08/04 09:00
MHDA- 2009/12/16 06:00
PMCR- 2010/11/01
CRDT- 2009/08/04 09:00
PHST- 2008/05/21 00:00 [received]
PHST- 2009/01/08 00:00 [revised]
PHST- 2009/01/09 00:00 [accepted]
PHST- 2009/08/04 09:00 [entrez]
PHST- 2009/08/04 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
PHST- 2010/11/01 00:00 [pmc-release]
AID - S0090-4295(09)00387-2 [pii]
AID - 10.1016/j.urology.2009.01.087 [doi]
PST - ppublish
SO  - Urology. 2009 Nov;74(5):1156-61. doi: 10.1016/j.urology.2009.01.087. Epub 2009 
      Aug 3.